Objective: To investigate the efficacy of ACBT for acquired SAA in children.
| INTRODUC TI ON
Aplastic anemia is defined as peripheral blood pancytopenia caused by bone marrow failure; the pathogenesis of this disease is thought to involve autoimmune processes. 1, 2 The principal interventions used to improve the survival of aplastic anemia patients are BMT and IST. SCTfrom an HLA-matched family donor is the treatment choice for SAA 1, [3] [4] [5] in children. In the last two decades, a significant improvement in outcome has been reported in patients with acquired SAA undergoing MDS or unrelated donor HCT. [6] [7] [8] Reports of using peripheral blood stem cells and cord blood for autologous HCT in aplastic anemia have been rare [9] [10] [11] [12] and were only limited to a few cases. We report the outcomes of four cases with acquired SAA receiving autologous cord blood transplantation (ACBT) to evaluate the therapeutic effect.
| PATIENTS AND ME THODS

| Patients
From March 2009 to October 2016, four patients including three girls and one boy were diagnosed with acquired SAA. They were 5, 3, 1 year and 8 months, and 3 years and 8 months old, respectively.
Next-generation gene sequencing test, chromosome breaking test, comet assay, and detecting for CD55 and CD59 by flow cytometry were performed on all the four patients, and no single case of IBMF was found.
| Pretreatment regimen
All patients received the same preparative regimen with ATG 
| Infusion
Autologous cord blood units were transfused on day 0 after the unrelated human umbilical cord MSC infusion. MSC was 
| Immunosuppressive agents
The first and second patients were not treated with immunosuppressive agents after transplantation. The third and the fourth patients received oral cyclosporine A for half a year after transplantation, and then gradually reduced 1/4 of the total dose every 2 weeks and stopped the medicines after half a year.
| Prevention and treatment of infections
Prophylactic measures for bacterial, fungal, and viral infections were taken during pretreatment and after the pretreatment. 
| RE SULTS
| Patient characteristics
Patient characteristics are shown in Table 1 (please see Table 1 ).
| Reconstitution
All the four patients achieved hematopoietic recovery. The time to neutrophil engraftment after the transplant was +21, +23, +19, and +23 days, respectively (please see Figure 1 ). The time to platelet engraftment was +23, +25, +28, and +26 days, respectively (please 
| Case 2
The second patient suffered from severe bacterial and fungal infection with fungal pneumonia, bacterial urethritis, and skin parenchyma inflammation. The result of blood culture was MASA, and urine culture was Escherichia coli-positive (Figures 3 and 4) . 
| Cases 3 and 4
Considering the first patient's relapse was perhaps associated with the lack of IST, the third and fourth patients received routine cyclosporine administration from pretreatment to 6 months after transplant with full dose and followed by a 6-month taper. The pretransplant recovery and post-transplant were also uncomplicated.
After transplantation, both patients achieved normal persistent hematopoiesis, and they have survived so far for 2 and 1 year, respectively, with good quality of life (see Table 1 ).
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| D ISCUSS I ON
Acquired SAA is a life-threatening diagnosis due to the high risk of severe infections and the need for multiple transfusions to prevent bleeding complications. Allogeneic SCT from an HLA-MSD is the preferred first-line treatment for younger SAA patients. 13, 14 When a sibling donor is not available, alternative donor SCT can be considered; however, significant risks, including GVHD and graft failure, often limit the use of alternative donors as the first line of treatment. [15] [16] [17] [18] Autologous SCT utilizing previously banked cord blood provides a clinical approach would avoid the risk of both graft failure and GVHD [19] [20] [21] .
In our report, three of the four patients achieved stable hematopoietic reconstitution. The neutrophils and platelet recovery did not seem to be impacted by total number of cells and CD34-positive cells counts; however, our sample size was too small to make firm conclusions regarding cord blood dose and count recovery. The four patients received reduced-intensity IST and transfusion of MSC before transfusion of the autologous cord blood. Due to the IST and the application of MSC before the transplantation, the successful engraftment of autologous cord blood was ensured as well as there was no association between engraftment time and the number of total cells or CD34+ cells.
Because the first patient did not receive IST after the transplantation and was a relapse after 6 months, the IST before and after transplantation is beneficial for the SAA patients with durable hematopoietic reconstitution. The application of MSC was considered to improve the bone marrow microenvironment and participate in the F I G U R E 2 PCT counts of four patients F I G U R E 3 Lung CT scan of case 2, before engraftment F I G U R E 4 Lung CT scan of case 2, 2 months after engraftment IST. MSC played a subsidiary role for good prognosis in the study, which still needs more cases practice and control study in the future.
Because the dose of cyclophosphamide and ATG was significantly reduced, the toxicity related to preparative regimen was significantly decreased compared with allogeneic transplantation or immune therapy to aplastic anemia. We cannot definitively exclude that the immunoablative properties of the fludarabine, cyclophosphamide, ATG, or cyclosporine were responsible for recovery of normal hematopoiesis in our patients, since both ATG and cyclosporine have been used as standard IST for acquired SAA. 22 The kinetics of our patients' hematopoietic recovery, neutrophil, and platelet engraftment within 30 days post-SCT suggests that the cord blood unit engrafted or at least helped to hasten transfusion independence.
It may be beneficial to use prolonged immunosuppression such as cyclosporine or tacrolimus to maintain the stability of the treatment effect and avoid the recurrence of the disease after the autologous umbilical cord blood transplantation for SAA. Disease recurrence in the first case may be associated with the absence of immunosuppression after the transplant. However, we cannot entirely exclude the IBMF syndromes based on the limitations of our screening pretransplant. Given the lessons learned from the first patient, the third and fourth patients received cyclosporine for a period of 6 months after the transplant and then tapered by X months. These two patients have maintained adequate hematopoiesis for 2 and 1 year.
In China, childhood SAA is considered a serious hematologic disease next only to leukemia. Because of limited availability of autologous umbilical cord blood, ACBT treatment is limited for children with SAA. In China, the umbilical cord blood storage permeability was only 1% (the data came from China industry information network, January 2016). Umbilical cord blood obtained at birth is a valuable source of stem cells. We expect more SAA cases can be treated effectively using autologous umbilical cord blood and that more children can benefit from this therapy.
In summary, autologous cord blood transplant following immunoablative therapy for SAA was associated with rapid hematopoietic recovery. In this small cohort, there did not seem to be an impact of cell dose on the likelihood of count recovery, though two of the four patients received >3 × 10 7 TNC/kg, which is considered the optimal cord blood dose. A significant improvement in the quality of life can be expected for children with good psychological and physiological development without chronic GVHD. It is recommended that cyclosporine should be maintained for 6 months after transplantation so as to avoid recurrence.
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